Atezolizumab and bevacizumab for upfront unresectable HCC
HTML-код
- Опубликовано: 27 сен 2019
- Michael Lee, MD, of UNC Lineberger Cancer Center, Chapel Hill, NC, explains the efficacy and safety results for atezolizumab and bevacizumab for patients with previously untreated, unresectable hepatocellular carcinoma (NCT02715531). He goes onto discuss the IMbrave150 study (NCT03434379). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
